Welcome to our dedicated page for Benitec Biopharm SEC filings (Ticker: BNTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Benitec Biopharma’s gene-silencing breakthroughs inside a 10-K or 8-K can feel like wading through lab notebooks. Clinical timelines, ddRNAi patent tables, and R&D expenses sprawl over hundreds of pages, while Benitec Biopharma insider trading Form 4 transactions surface at unpredictable hours. Stock Titan answers the problem by pairing real-time EDGAR feeds with AI that translates biotech jargon into plain language you can act on.
Need the next cash-runway update? Our platform flags it the moment a Benitec Biopharma quarterly earnings report 10-Q filing drops. Curious whether executives are adding shares before a BB-301 trial read-out? Receive instant alerts on Benitec Biopharma Form 4 insider transactions real-time. Each document arrives with an AI-powered summary that highlights pipeline milestones, licensing revenue, and risk factors—Benitec Biopharma SEC filings explained simply.
Explore every filing type in one place:
- 10-K: R&D spend, patent life, and Benitec Biopharma annual report 10-K simplified
- 10-Q: quarter-over-quarter trial costs and Benitec Biopharma earnings report filing analysis
- 8-K: clinical data releases with Benitec Biopharma 8-K material events explained
- DEF 14A: Benitec Biopharma proxy statement executive compensation decoded
- Form 4: Benitec Biopharma executive stock transactions Form 4 tracked to the minute
Whether you’re benchmarking cash burn or understanding Benitec Biopharma SEC documents with AI, Stock Titan condenses complexity into clear insights, so you spend time on decisions, not documentation.
OneStream, Inc. (OS) Form 4 filing: Director Jonathan D. Mariner sold 6,630 Class A common shares on 07/07/2025 at a weighted-average price of $26.59 under a Rule 10b5-1 trading plan adopted on 02/28/2025. After the sale, Mariner still beneficially owns 40,280 shares, which include unvested restricted stock units. No derivative transactions were reported.
The transaction reduces Mariner’s direct holdings by roughly 14% but maintains a sizable position, suggesting portfolio rebalancing rather than a full exit. The use of a pre-arranged plan limits the signaling effect because it indicates the sale was scheduled in advance and not driven by new, undisclosed information.
FAQ
What is the current stock price of Benitec Biopharm (BNTC)?
What is the market cap of Benitec Biopharm (BNTC)?
What is the primary technology behind Benitec Biopharma's therapies?
Which diseases does Benitec Biopharma target?
How does the Silence and Replace mechanism work?
What distinguishes Benitec's ddRNAi technology from traditional approaches?
Is Benitec involved in clinical development?
How is Benitec protecting its innovative technology?
How does the company generate revenue?
How does Benitec differentiate itself from competitors?
